Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.

Turpin, Anthony; Descarpentries, Clotilde; Grégoire, Valérie; Farchi, Olivier; Cortot, Alexis B; Jamme, Philippe

Turpin, Anthony; Descarpentries, Clotilde; Grégoire, Valérie; Farchi, Olivier; Cortot, Alexis B; Jamme, Philippe.

Afiliação

Turpin A; Medical Oncology Department, CHU Lille, University of Lille, Lille, France.
Descarpentries C; Department of Biochemistry and Molecular Biology, Hormonology Metabolism Nutrition Oncology, CHU Lille, University of Lille, Lille, France.
Grégoire V; Pathology Department, CHU Lille, University of Lille, Lille, France.
Farchi O; Department of Biochemistry and Molecular Biology, Hormonology Metabolism Nutrition Oncology, CHU Lille, University of Lille, Lille, France.
Cortot AB; Thoracic Oncology Department, CHU Lille, University of Lille, Lille, France.
Jamme P; Department of Dermatology, Hopital Claude Huriez, CHU Lille, University of Lille, France.

Oncologist ; 28(1): 80-83, 2023 01 18.

Article em En | MEDLINE | ID: mdl-36434677

Assuntos

Neoplasias dos Ductos Biliares; Colangiocarcinoma; Neoplasias Hepáticas; Humanos; Neoplasias dos Ductos Biliares/tratamento farmacológico; Neoplasias dos Ductos Biliares/genética; Ductos Biliares Intra-Hepáticos; Colangiocarcinoma/tratamento farmacológico; Colangiocarcinoma/genética; Neoplasias Hepáticas/tratamento farmacológico; Neoplasias Hepáticas/genética

Palavras-chave

MET; cholangiocarcinoma; precision medicine; resistance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Neoplasias Hepáticas Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google